Efficacy and Safety of Oral Erlotinib in TRPV3-related Olmsted Syndrome: a Case Series
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://data.mendeley.com/datasets/ppxxcgpz9b
下载链接
链接失效反馈官方服务：
资源简介：
Supplementary figures (A-B, C-D). Clinical images of OS patients treated with erlotinib
A and B, patient 10, with the TRPV3 p.Gly573Ser mutation, achieved complete remission of hyperkeratosis.
C and D, patient 9, with the TRPV3 p.Met672Ile mutation, exhibited only partial remission of skin hyperkeratosis.
Supplementary figures (E, F). Adverse effects of 2 patients treated with erlotinib
E, Severe acneiform eruption in patient 3 after two weeks of erlotinib treatment.
F, Diffuse hair loss in patient 2 after two months of erlotinib treatment.
Supplementary figures (G-I). Immunofluorescence staining of phospho-epidermal growth factor receptor (p-EGFR) in normal control, patient 9, and patient 4 before erlotinib treatment.
创建时间：
2025-06-12
